Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients

Acta Haematologica

Volumn 115, Issue 3-4, 2006, Pages 230-236

  Merkel, Nick ^a   Günther, Gudrun ^b   Schobess, Rosemarie ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Enoxaparin; Long term treatment; Pediatric; Thrombosis

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG; XA ANTIBODY;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BRAIN HEMORRHAGE; CEREBRAL SINUS THROMBOSIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; INFANT; INFLAMMATION; LONG TERM CARE; MALE; NEUROSURGERY; NEWBORN; NONHODGKIN LYMPHOMA; ORAL CONTRACEPTION; PEDIATRICS; PILOT STUDY; POSTOPERATIVE PERIOD; POSTTRAUMATIC COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SUBSTANCE ABUSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR PATENCY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; PILOT PROJECTS; THROMBOSIS;

EID: 33645127479     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090940     Document Type: Article

References (59)

1. Andrew M: Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74:415-425.
2. Gurgey A, Balta G, Gumruk F, Altay C: Analysis of some clinical and laboratory aspects of adolescent patients with thrombosis. Blood Coagul Fibrinolysis 2004;15:657-662.
3. Casais P, Meschengieser SS, Gennari LC, Alberto MF, Sanchez-Luceros A, Blanco AN, Lazzari MA: Morbidity of lupus anticoagulants in children: a single institution experience. Thromb Res 2004;114:245-249.
4. Obermoser G, Bitterlich W, Kunz F, Sepp NT: Clinical significance of anticardiolipin and anti-beta2-glycoprotein I antibodies. Int Arch Allergy Immunol 2004;135:148-153.
5. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M: Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998;133:770-776.
6. Schmidt B, Andrew M: Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995;96:939-943.
7. Glaser DW, Medeiros D, Rollins N, Buchanan GR: Catheter-related thrombosis in children with cancer. J Pediatr 2001;138:255-259.
8. Molinari AC, Castagnola E, Mazzola C, Piacentino M, Fratino G: Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters. Support Care Cancer 2001;9:539-544.
9. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M: Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. Blood 1994;83:386-391.
10. Lane DA, Grant PJ: Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000;95:1517-1532.
11. Junker R, Koch HG, Auberger K, Munchow N, Ehrenforth S, Nowak-Gottl U: Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol 1999;19:2568-2572.
12. Nowak-Gottl U, Junker R, Hartmeier M, Koch HG, Munchow N, Assmann G, von Eckardstein A: Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999;100:743-748.
13. Vielhaber H, Ehrenforth S, Koch HG, Scharrer I, van der Werf N, Nowak-Gottl U: Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia. Eur J Pediatr 1998;157:555-560.
14. deVeber G, Andrew M; Canadian Pediatric Ischemic Stroke Study Group: Cerebral sinovenous thrombosis in children. N Engl J Med 2001;345:417-423.
15. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L: Maturation of the hemostatic system during childhood. Blood 1992;80:1998-2005.
16. Ruud E, Holmstrom H, Natvig S, Wesenberg F: Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer - a prospective study. Med Pediatr Oncol 2002;38:405-410.
17. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN: Effect of L-asparaginase administration on coagulation and platelet function in children with leukaemia. J Clin Oncol 1987;5:811-817.
18. Semeraro N, Montemurro P, Giordano P, Schettini F, Santoro N, DeMattia D, Giordano D, Conese M, Colucci M: Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia. Thromb Haemost 1990;64:38-40.
19. Miniero R, Saracco P, Einaudi S, Garofalo F, Lange MM, Madon E: L-Asparaginase-induced coagulopathy in children with acute lymphoblastic leukaemia. Drugs Exp Clin Res 1987;13:377-379.
20. Shapiro AD, Clarke SL, Christian JM, Odom LF, Hathaway WE: Thrombosis in children receiving L-asparaginase. Determining patients at risk. Am J Pediatr Hematol Oncol 1993;15:400-405.
21. Reddingius RE, Patte C, Couanet D, Kalifa C, Lemerle J: Dural sinus thrombosis in children with cancer. Med Pediatr Oncol 1997;29:296-302.
22. Heller C, Heinecke A, Junker R, Knofler R, Kosch A, Kurnik K, Schobess R, von Eckardstein A, Strater R, Zieger B, Nowak-Gottl U; Childhood Stroke Study Group: Cerebral venous thrombosis in children: a multifactorial origin. Circulation 2003;108:1362-1367.
23. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U: Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 2000;83:840-843.
24. Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R: Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001;103:165-172.
25. Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D, Schobess R, Schumann C, Junker R: Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003;101:2529-2533.
26. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, Andrew M; REVIVE Study Group: An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003;109:85-92.
27. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M: Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128:313-318.
28. Sutor AH, Massicotte P, Leaker M, Andrew M: Heparin therapy in pediatric patients. Semin Thromb Hemost 1997;23:303-319.
29. deVeber G, Chan A, Monagle P, Marzinotto V, Armstrong D, Massicotte P, Leaker M, Andrew M: Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study. Arch Neurol 1998;55:1533-1537.
30. Massicotte MP: Low-molecular-weight heparin therapy in children. J Pediatr Hematol Oncol 2000;22:98-99.
31. Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, deVeber G, Leaker M, Chan AK, Massicotte MP: The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000;136:439-445.
32. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, Andrew M; REVIVE Study Group: An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003;109:85-92.
33. Massicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK, Szechtman B, Kohne S, Shepherd S, Bacher P, Andrew M: Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003;109:93-99.
34. Streif W, Goebel G, Chan AK, Massicotte MP: Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed 2003;88:F365-F370.
35. Levy DM, Massicotte MP, Harvey E, Hebert D, Silverman ED: Thromboembolism in paediatric lupus patients. Lupus 2003;12:741-746.
36. Revel-Vilk S, Sharathkumar A, Massicotte P, Marzinotto V, Daneman A, Dix D, Chan A: Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. J Thromb Haemost 2004;2:42-46.
37. Sutor AH, Chan AK, Massicotte P: Low-molecular-weight heparin in pediatric patients. Semin Thromb Hemost 2004;30(suppl 1):31-39.
38. Anton N, Massicotte MP: Venous thromboembolism in pediatrics. Semin Vasc Med 2001;1:111-122.
39. Andrew M: Developmental hemostasis: relevance to hemostatic problems during childhood. Semin Thromb Hemost 1995;21:341-356.
40. Beardsley DS: Hemostasis in the perinatal period: approach to the diagnosis of coagulation disorders. Semin Perinatol 1991;15(3 suppl 2):25-34.
41. Nowak-Gottl U, Kosch A, Schlegel N: Neonatal thromboembolism. Semin Thromb Hemost 2003;29:227-234.
42. Nowak-Gottl U, Kosch A, Schlegel N, Salem M, Manco-Johnson M: Thromboembolism in children. Curr Opin Hematol 2002;9:448-453.
43. Nowak-Gottl U, Kosch A, Schlegel N: Thromboembolism in newborns, infants and children. Thromb Haemost 2001;86:464-474.
44. Ho SH, Wu JK, Hamilton DP, Dix DB, Wadsworth LD: An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review. J Pediatr Hematol Oncol 2004;26:561-566.
45. Michaels LA, Gurian M, Hegyi T, Drachtman RA : Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics 2004;114:703-707.
46. Vieira A, Berry L, Ofosu F, Andrew M: Heparin sensitivity and resistance in the neonate: an explanation. Thromb Res 1991;63:85-98.
47. Andrew M, Ofosu F, Brooker L, Buchanan MR: The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig. Thromb Res 1989;56:529-539.
48. Albisetti M, Andrew M: Low molecular weight heparin in children. Eur J Pediatr 2002;161:71-77.
49. Hofmann S, Knoefler R, Lorenz N, Siegert G, Wendisch J, Mueller D, Taut-Sack H, Dinger J, Kabus M: Clinical experiences with low-molecular weight heparins in pediatric patients. Thromb Res 2001;103:345-353.
50. Manco-Johnson MJ, Nuss R, Hays T, Krupski W, Drose J, Manco-Johnson ML: Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000;136:446-453.
51. Kosch A, Kuwertz-Broking E, Heller C, Kurnik K, Schobess R, Nowak-Gottl U: Renal venous thrombosis in neonates: prothrombotic risk factors and long-term follow-up. Blood 2004;104:1356-1360.
52. Shevell MI, Silver K, O'Gorman AM, Watters GV, Montes JL: Neonatal dural sinus thrombosis. Pediatr Neurol 1989;5:161-165.
53. West WM, Brady-West D: Ultrasonography of the lower limbs for deep vein thrombosis at the University Hospital of the West Indies. A five-year analysis. West Indian Med J 2002;51:35-36.
54. Giannoukas AD, Fatouros M, Batsis H, Mitsis M, Matsagas M, Koulouras V, Tsampoulas C, Kappas M, Cassioumis A: Symptomatic deep venous thrombosis of the lower limb. Int Angiol 1998;17:151-154.
55. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, Bernstein M, Brisson L, Cairney B, DeSai D, et al: Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83:1251-1257.
56. Manco-Johnson MJ, Grabowski EF, Hellgreen M, Kemahli AS, Massicotte MP, Muntean W, Peters M, Schlegel N, Wang M, Nowak-Gottl U: Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002;88: 157-158.
57. Connor SE, Jarosz JM: Magnetic resonance imaging of cerebral venous sinus thrombosis. Clin Radiol 2002;57:449-461.
58. Ip BK, Thomson AR, Moriarty HAT: A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin. Pathology 2001;33:347-352.
59. Koppenhagen K: Enoxaparin - Im Zeichen der Unverwechselbarkeit. Klinikarzt 2004;33(suppl):8-9.